SOPHiA GENETICS
SOPHiA GENETICS's revenue rose 18.6% to $77 million in fiscal 2025. Its operating margin was −91.8%, up from −102.1% a year earlier. Free cash flow was −$36 million. The diluted share count rose 2.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Income statement
SOPHiA GENETICS lost money in fiscal 2025: a net loss of $79 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 193 | 161 | 123 | 80 | 70 |
| Debt incl. finance leases | — | — | 0 | 13 | 48 |
| Net debt (negative means net cash) | — | — | −123 | −67 | −23 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | 0.1x | 1.0x |
| Interest coverage | −108.7x | −137.4x | −127.3x | −34.8x | −15.6x |
| Current ratio | 9.9x | 7.3x | 4.2x | 3.7x | 2.0x |
| Quick ratio | 9.7x | 7.1x | 4.0x | 3.5x | 1.8x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 3 of 9 | 2 of 9 |
| Rule of 40 | −56.6% | −64.2% | −28.6% |
| Altman Z'' | −1.93 | −7.33 | −10.93 |
| Accruals ratio | −11.4% | −9.9% | −27.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | Fail | Fail |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | 3 of 9 | 2 of 9 |
Compare
Put SOPHiA GENETICS side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| SOPHiA GENETICS | FY25 | 18.6% | −91.8% | −47.2% | −207.1% | — | 2 | |
| OptimizeRx | FY25 | 18.8% | 10.7% | 17.1% | 6.4% | 0.2x | 8 | Compare |
| CareCloud | FY25 | 8.7% | 9.4% | 19.7% | 21.5% | −0.1x | 5 | Compare |
| NRC Health | FY25 | −4.0% | 16.4% | 11.5% | 16.4% | 2.5x | 5 | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 25 | 28 | 40 | 48 | 62 | 65 | 77 |
| Revenue growth | — | 12.0% | 42.4% | 17.6% | 31.1% | 4.5% | 18.6% |
| Gross profit | 18 | 18 | 25 | 31 | 43 | 44 | 52 |
| Research and development | 15 | 19 | 27 | 35 | 37 | 34 | 34 |
| Operating income | — | −37 | −72 | −88 | −75 | −67 | −71 |
| Net income | −34 | −39 | −74 | −87 | −79 | −62 | −79 |
| Diluted EPS (US$) | — | −0.93 | −1.33 | −1.36 | −1.22 | −0.95 | −1.17 |
| Diluted shares (millions) | — | 42 | 55 | 64 | 65 | 66 | 68 |
| Cash flow | |||||||
| Cash from operations | −32 | −32 | −58 | −70 | −53 | −44 | −36 |
| Capital expenditure | 1 | 0 | 3 | 4 | 2 | 0 | 1 |
| Free cash flow | −33 | −32 | −61 | −74 | −55 | −45 | −36 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 8 | 14 | 15 | 16 | 16 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 18 | 75 | 193 | 161 | 123 | 80 | 70 |
| Debt incl. finance leases | — | 3 | — | — | 0 | 13 | 48 |
| Total assets | — | 132 | 320 | 244 | 206 | 155 | 163 |
| Total liabilities | — | 32 | 45 | 44 | 55 | 59 | 116 |
| Shareholders' equity | 22 | 100 | 275 | 200 | 151 | 96 | 47 |
| Margins and ratios | |||||||
| Gross margin | 70.3% | 62.3% | 62.4% | 65.7% | 68.8% | 67.4% | 67.4% |
| Operating margin | — | −131.6% | −176.7% | −184.7% | −120.0% | −102.1% | −91.8% |
| Net margin | −133.2% | −138.5% | −182.1% | −183.9% | −126.6% | −95.9% | −102.2% |
| Free cash flow margin | −130.2% | −113.3% | −149.9% | −156.0% | −87.7% | −68.7% | −47.2% |
| Rule of 40 (growth + FCF margin) | — | −101.3% | −107.4% | −138.4% | −56.6% | −64.2% | −28.6% |
| Return on capital | — | — | — | — | — | −182.3% | −207.1% |
| Return on equity | — | — | −39.2% | −36.8% | −44.9% | −50.4% | −110.0% |
| Return on assets | — | — | −32.6% | −31.0% | −35.1% | −34.6% | −49.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — |